A review of new science, in plain language

Nature Medicine  ·  6 August 2026  ·  From issue 17

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial

A single psilocybin dose cut depression scores far more than a placebo in hard to treat depression.

James J. Rucker, Tim Mantingh et al.

A single dose of the drug psilocybin, given with talk therapy support, lowered depression scores much more than a placebo in people whose depression had not improved with other treatments. Sixty people took part at one hospital in England. Almost everyone stayed in the study and finished all check-ins. The benefit showed up after three weeks and was still there at six weeks.

Integrity screen: passed (3 checks) Checked 20 September 2026. Read the source

The plain-language reading of this paper is in the full issue, for subscribers.

Read the full issue

Five vetted papers in plain language, free, every two days

Five papers free every issue, about 15 emails a month. No spam. Leave in one click.

Also in issue 17 15 papers
More from Nature Medicine